Top

Published in:

Open Access 01-12-2023 | Breast Cancer | Research

Downregulation of TAB182 promotes cancer stem-like cell properties and therapeutic resistance in triple-negative breast cancer cells

Authors: Huan He, Shaozheng Wang, Wen Zhang, Shanshan Gao, Hua Guan, Pingkun Zhou

Published in: BMC Cancer | Issue 1/2023

Abstract

TAB182 participates in DNA damage repair and radio-/chemosensitivity regulation in various tumors, but its role in tumorigenesis and therapeutic resistance in breast cancer remains unclear. In the current paper, we observed that triple-negative Breast Cancer (TNBC), a highly aggressive type of breast cancer, exhibits a lower expression of TAB182. TAB182 knockdown stimulates the proliferation, migration, and invasion of TNBC cells. Our study first obtained RNA-seq data to explore the cellular functions mediated by TAB182 at the genome level in TNBC cells. A transcriptome analysis and in vitro experiments enabled us to identify that TAB182 downregulation drives the enhanced properties of cancer stem-like cells (CSCs) in TNBC cells. Furthermore, TAB182 deletion contributes to the resistance of cells to olaparib or cisplatin, which can be rescued by silencing GLI2, a gene downstream of cancer stemness-related signaling pathways. Our results reveal a novel function of TAB182 as a potential negative regulator of cancer stem-like properties and drug sensitivity in TNBC cells, suggesting that TAB182 may be a tumor suppressor gene and is associated with increased therapeutic benefits for TNBC patients.

Available only for authorised users

Zagami P, Carey LA. Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer. 2022;8(1):95. https://doi.org/10.1038/s41523-022-00468-0.CrossRefPubMedPubMedCentral

Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34. https://doi.org/10.1158/1078-0432.Ccr-06-3045.CrossRefPubMed

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–90. https://doi.org/10.1038/nrclinonc.2016.66.CrossRefPubMedPubMedCentral

Hill DP, Harper A, Malcolm J, et al. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance. BMC Cancer. 2019;19(1):1039. https://doi.org/10.1186/s12885-019-6278-9.CrossRefPubMedPubMedCentral

Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133(3):831–41. https://doi.org/10.1007/s10549-011-1891-6.CrossRefPubMed

Kim DS, Camacho CV, Kraus WL. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med. 2021;53(1):42–51. https://doi.org/10.1038/s12276-021-00557-3.CrossRefPubMedPubMedCentral

Fatima Cardoso VK. Vivianne Tjan-Heijnen. Breast Cancer Essentials for Clinicians: ESMO Press; 2017.

Muvarak Nidal E, Chowdhury K, Xia L, et al. Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents & #x2013; A Potential Therapy for Cancer. Cancer Cell. 2016;30(4):637–50. https://doi.org/10.1016/j.ccell.2016.09.002.CrossRefPubMedPubMedCentral

Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125(3):627–36. https://doi.org/10.1007/s10549-010-1293-1.CrossRefPubMed

10.

Eiermann W, Vallis KA. Locoregional treatments for triple-negative breast cancer. Ann Oncol. 2012;23(Suppl 6):vi30–4.CrossRefPubMed

11.

Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24(36):5652–7. https://doi.org/10.1200/jco.2006.06.5664.CrossRefPubMed

12.

Kiss RC, Xia F, Acklin S. Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment. Int J Mol Sci. 2021;22(15):8199. https://doi.org/10.3390/ijms22158199.CrossRefPubMedPubMedCentral

13.

Caparica R, Lambertini M, de Azambuja E. How I treat metastatic triple-negative breast cancer. ESMO Open. 2019;4(Suppl 2):e000504. https://doi.org/10.1136/esmoopen-2019-000504.CrossRefPubMedPubMedCentral

14.

Lohse I, Borgida A, Cao P, et al. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer. 2015;113(3):425–32. https://doi.org/10.1038/bjc.2015.220.CrossRefPubMedPubMedCentral

15.

Gote V, Nookala AR, Bolla PK, Pal D. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue. Int J Mol Sci. Apr 28 2021;22(9) https://doi.org/10.3390/ijms22094673

16.

Garcia-Martinez L, Zhang Y, Nakata Y, Chan HL, Morey L. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021;12(1):1786. https://doi.org/10.1038/s41467-021-22024-3.CrossRefPubMedPubMedCentral

17.

Li Y, Wang Z, Ajani JA, Song S. Drug resistance and Cancer stem cells. Cell Commun Signal. 2021;19(1):19. https://doi.org/10.1186/s12964-020-00627-5.CrossRefPubMedPubMedCentral

18.

Honeth G, Bendahl PO, Ringnér M, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10(3):R53. https://doi.org/10.1186/bcr2108.CrossRefPubMedPubMedCentral

19.

Park S-Y, Choi J-H, Nam J-S. Targeting Cancer Stem Cells in Triple-Negative Breast Cancer. Cancers (Basel). 2019;11(7):965. https://doi.org/10.3390/cancers11070965.CrossRefPubMed

20.

Steinbichler TB, Dudás J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova I-I. Therapy resistance mediated by cancer stem cells. Semin Cancer Biol. 2018;53:156–67. https://doi.org/10.1016/j.semcancer.2018.11.006.CrossRefPubMed

21.

Yadav AK, Desai NS. Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects. Stem Cell Rev Rep. 2019;15(3):331–55. https://doi.org/10.1007/s12015-019-09887-2.CrossRefPubMed

22.

Seimiya H, Smith S. The telomeric poly(ADP-ribose) polymerase, tankyrase 1, contains multiple binding sites for telomeric repeat binding factor 1 (TRF1) and a novel acceptor, 182-kDa tankyrase-binding protein (TAB182). J Biol Chem. 2002;277(16):14116–26. https://doi.org/10.1074/jbc.M112266200.CrossRefPubMed

23.

Sbodio JI, Chi NW. Identification of a tankyrase-binding motif shared by IRAP, TAB182, and human TRF1 but not mouse TRF1 NuMA contains this RXXPDG motif and is a novel tankyrase partner. J Biol Chem. 2002;277(35):31887–92. https://doi.org/10.1074/jbc.M20391620010.1074/jbc.M203916200.CrossRefPubMed

24.

Ohishi T, Yoshida H, Katori M, et al. Tankyrase-Binding Protein TNKS1BP1 Regulates Actin Cytoskeleton Rearrangement and Cancer Cell Invasion. Cancer Res. 2017;77(9):2328–38. https://doi.org/10.1158/0008-5472.Can-16-1846.CrossRefPubMed

25.

Lau NC, Kolkman A, van Schaik FM, et al. Human Ccr4-Not complexes contain variable deadenylase subunits. Biochem J. 2009;422(3):443–53. https://doi.org/10.1042/bj20090500.CrossRefPubMed

26.

Meijer HA, Schmidt T, Gillen SL, et al. DEAD-box helicase eIF4A2 inhibits CNOT7 deadenylation activity. Nucleic Acids Res. 2019;47(15):8224–38. https://doi.org/10.1093/nar/gkz509.CrossRefPubMedPubMedCentral

27.

Chalabi Hagkarim N, Grand RJ. The Regulatory Properties of the Ccr4-Not Complex. Cells. Oct 29 2020;9(11) https://doi.org/10.3390/cells9112379

28.

Tan W, Guan H, Zou LH, et al. Overexpression of TNKS1BP1 in lung cancers and its involvement in homologous recombination pathway of DNA double-strand breaks. Cancer Med. 2017;6(2):483–93. https://doi.org/10.1002/cam4.995.CrossRefPubMedPubMedCentral

29.

Zou LH, Shang ZF, Tan W, et al. TNKS1BP1 functions in DNA double-strand break repair though facilitating DNA-PKcs autophosphorylation dependent on PARP-1. Oncotarget. 2015;6(9):7011–22. https://doi.org/10.18632/oncotarget.3137.CrossRefPubMedPubMedCentral

30.

Cao Y, Gao A, Li X, et al. Elevated TAB182 enhances the radioresistance of esophageal squamous cell carcinoma through G2-M checkpoint modulation. Cancer Med. 2021;10(9):3101–12. https://doi.org/10.1002/cam4.3879.CrossRefPubMedPubMedCentral

31.

Chalabi Hagkarim N, Ryan EL, Byrd PJ, et al. Degradation of a Novel DNA Damage Response Protein, Tankyrase 1 Binding Protein 1, following Adenovirus Infection. J Virol. Jun 15 2018;92(12) https://doi.org/10.1128/JVI.02034-17

32.

Borowicz S, Van Scoyk M, Avasarala S, et al. The soft agar colony formation assay. J Vis Exp. 2014;92:e51998. https://doi.org/10.3791/51998.CrossRef

33.

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51. https://doi.org/10.1002/pro.3715.CrossRefPubMedPubMedCentral

34.

Gao A, Su Z, Shang Z, et al. TAB182 aggravates progression of esophageal squamous cell carcinoma by enhancing β-catenin nuclear translocation through FHL2 dependent manner. Cell Death Dis. 2022;13(10):900. https://doi.org/10.1038/s41419-022-05334-2.CrossRefPubMedPubMedCentral

35.

Wang S, Guo H, Jia J, et al. Silencing TAB182 inhibits cell EMT, migration and invasion by downregulating EGFR in A549 NSCLC cells. Mol Biol Rep. Jan 23 2023; https://doi.org/10.1007/s11033-022-08176-5

36.

Lappalainen P, Kotila T, Jégou A, Romet-Lemonne G. Biochemical and mechanical regulation of actin dynamics. Nat Rev Mol Cell Biol. 2022;23(12):836–52. https://doi.org/10.1038/s41580-022-00508-4.CrossRefPubMed

37.

Sun A, Li Y, Jiang X. CCL26 silence represses colon cancer by inhibiting the EMT signaling pathway. Tissue and Cell. 2022;79:101937. https://doi.org/10.1016/j.tice.2022.101937.CrossRefPubMed

38.

Figenschau SL, Knutsen E, Urbarova I, et al. ICAM1 expression is induced by proinflammatory cytokines and associated with TLS formation in aggressive breast cancer subtypes. Scientific Reports. 2018;8(1):11720. https://doi.org/10.1038/s41598-018-29604-2.CrossRefPubMedPubMedCentral

39.

Guo P, Huang J, Wang L, et al. ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci U S A. 2014;111(41):14710–5. https://doi.org/10.1073/pnas.1408556111.CrossRefPubMedPubMedCentral

40.

He H, Sinha I, Fan R, et al. c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer. Oncogene. 2018;37(19):2586–600. https://doi.org/10.1038/s41388-018-0165-8.CrossRefPubMed

41.

Fu M, Hu Y, Lan T, Guan K-L, Luo T, Luo M. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022;7(1):376. https://doi.org/10.1038/s41392-022-01191-9.CrossRefPubMedPubMedCentral

42.

Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120–8. https://doi.org/10.1016/j.gene.2019.02.076.CrossRefPubMed

43.

Peng L, Jiang J, Tang B, Nice EC, Zhang YY, Xie N. Managing therapeutic resistance in breast cancer: from the lncRNAs perspective. Theranostics. 2020;10(23):10360–77. https://doi.org/10.7150/thno.49922.CrossRefPubMedPubMedCentral

44.

Li L-y, Guan Y-d, Chen X-s, Yang J-m, Cheng Y. DNA Repair Pathways in Cancer Therapy and Resistance. Review. Frontiers in Pharmacology. 2021-February-08 2021;11 https://doi.org/10.3389/fphar.2020.629266

45.

Song D, He H, Sinha I, et al. Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor. Cancer Lett. 2021;506:23–34. https://doi.org/10.1016/j.canlet.2021.02.018.CrossRefPubMed

46.

Teraoka S, Muguruma M, Takano N, et al. Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines. J Surg Res. 2020;250:200–8. https://doi.org/10.1016/j.jss.2019.12.040.CrossRefPubMed

47.

Fultang N, Chakraborty M, Peethambaran B. Regulation of cancer stem cells in triple negative breast cancer. Cancer Drug Resist. 2021. https://doi.org/10.20517/cdr.2020.106.CrossRefPubMedPubMedCentral

48.

O’Conor CJ, Chen T, González I, Cao D, Peng Y. Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker. Biomark Med. 2018;12(7):813–20. https://doi.org/10.2217/bmm-2017-0398.CrossRef

49.

Meng E, Mitra A, Tripathi K, et al. ALDH1A1 Maintains Ovarian Cancer Stem Cell-Like Properties by Altered Regulation of Cell Cycle Checkpoint and DNA Repair Network Signaling. PLoS ONE. 2014;9(9):e107142. https://doi.org/10.1371/journal.pone.0107142.CrossRefPubMedCentral

50.

Liu YP, Yang CJ, Huang MS, et al. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res. 2013;73(1):406–16. https://doi.org/10.1158/0008-5472.Can-12-1733.CrossRefPubMed

51.

Yoshikawa K, Noguchi K, Nakano Y, et al. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma. Int J Oncol. 2015;46(6):2364–70. https://doi.org/10.3892/ijo.2015.2948.CrossRefPubMed

52.

Xu S, Zhang H, Chong Y, Guan B, Guo P. YAP Promotes VEGFA Expression and Tumor Angiogenesis Though Gli2 in Human Renal Cell Carcinoma. Arch Med Res. 2019;50(4):225–33. https://doi.org/10.1016/j.arcmed.2019.08.010.CrossRefPubMed

53.

Badouel C, McNeill H. SnapShot: The hippo signaling pathway. Cell. 2011;145(3):484–484.e1. https://doi.org/10.1016/j.cell.2011.04.009.CrossRefPubMed

54.

Tang Y-A, Chen Y-f, Bao Y, et al. Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer. Proceedings of the National Academy of Sciences. 2018;115(26):E5990.https://doi.org/10.1073/pnas.1801348115

55.

He M, Fu Y, Yan Y, et al. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients. Clin Sci (Lond). 2015;129(9):809–22. https://doi.org/10.1042/cs20140592.CrossRefPubMed

56.

Steg AD, Bevis KS, Katre AA, et al. Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer. Clin Cancer Res. 2012;18(3):869–81. https://doi.org/10.1158/1078-0432.Ccr-11-2188.CrossRefPubMed

57.

Mohammed MK, Shao C, Wang J, et al. Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis. 2016;3(1):11–40. https://doi.org/10.1016/j.gendis.2015.12.004.CrossRefPubMedPubMedCentral

58.

Hu W, Li M, Chen Y, Gu X. UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway. J Ovarian Res. 2021;14(1):121. https://doi.org/10.1186/s13048-021-00877-y.CrossRefPubMedPubMedCentral

59.

Yamamoto TM, McMellen A, Watson ZL, et al. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog. 2019;58(10):1770–82. https://doi.org/10.1002/mc.23064.CrossRefPubMedPubMedCentral

Title: Downregulation of TAB182 promotes cancer stem-like cell properties and therapeutic resistance in triple-negative breast cancer cells
Authors: Huan He
Shaozheng Wang
Wen Zhang
Shanshan Gao
Hua Guan
Pingkun Zhou
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11552-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Integrative analysis of the molecular signature of target genes involved in the antitumor effects of cantharidin on hepatocellular carcinoma

Exogenous hormone therapy and non-melanoma skin cancer (keratinocyte carcinoma) risk in women: a systematic review and meta-analysis

Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial—a study protocol

Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study

Serum and ascites tumor markers in the diagnostic and prognostic prediction for appendiceal pseudomyxoma peritonei

Risk model and factors for prediction of response to neoadjuvant chemotherapy in patients with advanced gastric cancer-a two-center cohort study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer